641
Views
7
CrossRef citations to date
0
Altmetric
Articles

Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information

, & ORCID Icon

References

  • Berger, J. O. (1985). Statistical Decision Theory and Bayesian Analysis. New York, NY: Springer-Verlag.
  • Bernardo, J. M., Smith, A. F. (1994). Introduction, in Bayesian Theory. Hoboken, NJ: John Wiley & Sons.
  • Berry, S. M., Carlin, B. P., Lee, J. J., Muller, P. (2011). Bayesian Adaptive Methods for Clinical Trials. Boca Raton, FL: CRC Press.
  • Calvez, T., Chambost, H., Claeyssens-Donadel, S., d’Oiron, R., Goulet, V., Guillet, B., et al. (2014). Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood 124(23):3398–3408.
  • Chen, M.-H., Ibrahim, J. G., Lam, P., Yu, A., Zhang, Y. (2011). Bayesian design of noninferiority trials for medical devices using historical data. Biometrics 67(3):1163–1170.
  • Chen, W.-C., Li, J., Scott, J., Mintz, P. (2015). Bayesian-Commensurate Approach for Safety Assessment in Clinical Studies with Count Outcomes. Joint Statistical Meetings 2015. Seattle, WA, USA. URL https://www.amstat.org/meetings/jsm/2015/onlineprogram/AbstractDetails.cfm?abstractid=317455
  • Collins, P. W., Palmer, B. P., Chalmers, E. A., Hart, D. P., Liesner, R., Rangarajan, S., et al. (2014). Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000–2011. Blood 124(23):3389–3397.
  • Dempster, A., Selwyn, M., Weeks, B. (1983). Combining historical and randomized controls for assessing trends in proportions. Journal of the American Statistical Association 78(382):221–227.
  • Gelfand, A. E., Smith, A. (1990). Sampling-based approaches to calculating marginal densities. Journal of the American Statistical Association 85:398–409.
  • Gouw, S. C., van der Bom, J. G., Auerswald, G., Ettinghausen, C., Tedgard, U., van den Berg, H. (2007). Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109(11):4693–4697.
  • Gouw, S. C., van der Bom, J. G., Ljung, R., Escuriola, C., Cid, A. R., Claeyssens-Donadel, S., et al. (2013). Factor VIII products and inhibitor development in severe hemophilia A. New England Journal of Medicine 368(3):231–239.
  • Gsteiger, S., Neuenschwander, B., Mercier, F., Schmidli, H. (2013). Using historical control information for the design and analysis of clinical trials with overdispersed count data. Statistics in Medicine 32:3609–3622.
  • Herbert, R. (1956). An empirical bayes approach to statistics. In Proceedings of the Third Berkeley Symposium on Mathematical Statistics and Probability. 1, pp. 157–163. Berkeley, CA: University of California Press.
  • Hobbs, B. P., Carlin, B. P., Mandrekar, S. J., Sargent, D. J. (2011). Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics 67(3):1047–1056.
  • Hobbs, B. P., Sargent, D. J., Carlin, B. P. (2012). Commensurate priors for incorporating historical information in clinical trials using general and generalized linear modles. Bayesian Analysis 7(3):639–674.
  • Ibrahim, J. G., Chen, M.-H. (2000). Power prior distributions for regression models. Statistical Science 15(1):46–60.
  • ICH. (2000). E10: Choice of Control Group in Clinical Trials. URL http://www.ich.org/
  • Morita, S., Thall, P. F., Müller, P. (2008). Determining the effective sample size of a parametric prior. Biometrics 64(2):595–602.
  • Morita, S., Thall, P. F., Müller, P. (2012). Prior effective sample size in conditionally independent hierarchical models. Bayesian Analysis 7(3):591–614.
  • Neuenschwander, B., Capkun-Niggli, G., Branson, M., Spiegelhalter, D. J. (2010). Summarizing historical information on controls in clinical trials. Clinical Trials 7:5–18.
  • Plummer, M. (2003). JAGS: A program for analysis of Bayesian Graphical Models using Gibbs Sampling. URL http://mcmc-jags.sourceforge.net/
  • Plummer, M. (2014). rjags: Bayesian Graphical Models using MCMC. URL http://cran.r-project.org/package=rjags
  • Pocock, S. J. (1976). The combination of randomized and historical controls in clinical trials. Journal of Chronic Diseases 29:175–188.
  • R Core Team. (2015). R: A Language and Environment for Statistical Computing. URL http://www.r-project.org/
  • Ryan, L. (1993). Using historical controls in the analysis of developmental toxicity data. Biometrics 49:1126–1135.
  • Schmidli, H., Gsteiger, S., Roychoudhury, S., O’Hagan, A., Spiegelhalter, D., Neuenschwander, B. (2014). Robust Meta-Analytic-Predictive priors in clinical trials with historical control information. Biometrics 70(4):1023–1032.
  • Viele, K., Berry, S., Neuenschwander, B., Amzal, B., Chen, F., Enas, N., et al. (2014). Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics 13(1):41–54.
  • Weaver, J., Ohlssen, D., Li, J. X. (2016). Strategies on using prior information when assessing adverse events. Statistics in Biopharmaceutical Research 8(1):106–115.
  • Wight, J., Paisley, S. (2003). The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9:418–315.
  • Yee, T. W. (2014). VGAM: Vector Generalized Linear and Additive Models. URL http://cran.r-project.org/package=VGAM

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.